U.S. markets closed

Mirati Therapeutics, Inc. (MRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
114.03-4.31 (-3.64%)
At close: 04:00PM EST
114.03 0.00 (0.00%)
After hours: 04:58PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close118.34
Bid114.01 x 800
Ask123.58 x 900
Day's Range113.01 - 120.00
52 Week Range113.01 - 225.47
Avg. Volume538,782
Market Cap6.302B
Beta (5Y Monthly)1.33
PE Ratio (TTM)N/A
EPS (TTM)-9.54
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est220.08
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MRTX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Mirati Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 01/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Zacks

    Amgen's (AMGN) KRAS Inhibitor Gets Nod in Japan for Lung Cancer

    Amgen's (AMGN) KRAS inhibitor, Lumakras, gets approval in Japan for the treatment of KRAS G12C-mutated positive advanced/recurrent non-small-cell lung cancer.

  • Benzinga

    Mirati Therapeutics Posts 41% Objective Response Rate In Pretreated GI Cancer Patients

    Mirati Therapeutics Inc (NASDAQ: MRTX) has announced data from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in pretreated patients with pancreatic ductal adenocarcinoma and other gastrointestinal (GI) tumors. As of September 10, 2021, the subset of patients with GI cancers harboring a KRASG12C mutation enrolled in the adagrasib monotherapy arm (n=30). Of the evaluable patients (n=27), the objective response rate (ORR) was 41%, and the disease control rate (D

  • PR Newswire

    Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers

    Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive results from a Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib at the 600mg BID dose in patients with pretreated pancreatic ductal adenocarcinoma and other gastrointestinal (GI) tumors harboring a KRASG12C mutation, including cancers of the biliary tract, appendix, small bowel, gastro-esophageal junction, and esophagus. Results showed that adagrasib demonstrated significant c